Bristol’s Amylin Deal Heralds Acquisition Hunger

Bristol-Myers Squibb Co.’s $5.3 billion deal to buy diabetes drugmaker Amylin Pharmaceuticals Inc. gives Bristol immediate access to a market of growing medical need, while heralding a burgeoning hunger among pharmaceutical companies for acquisitions.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.